Curis, Debiopharm Group Reports Debio 0932 Demonstrated Anti-Tumor Activity Benzinga Additionally, Debio 0932 also showed strong synergy with everolimus in multiple patient derived and conventional RCC cell lines. Similar synergy and anti-tumor activity with Debio 0932 in combination with these agents was also demonstrated in human ... |
